If recovery from such toxicities at a reduced dose was confirmed, administration at the reduced dose was continued. Patients who still experienced the same toxicity after the dose reduction were withdrawn from the study treatment. Statistical and ethical considerations The primary endpoint of the phase...
The i.v. rucaparib on an intermittent dosing schedule resulted in an ORR of only 2% but 41% (18 out of 44) of patients achieved SD for X12 weeks, with 3 patients maintaining disease stabilisation for 452 weeks (see Table 1). The low ORR combined with PD data showing recovery of ...
Du et al., has evaluated the recovery and reproducibility of five different peptide extraction methods (i.e., acetonitrile (ACN) precipitation[103],ultrafiltration[69], C18 solid-phase extraction (SPE), dispersed SPE with mesoporous carbon CMK-3[104], and mesoporous silica MCM-41[105]) using...
Examples included the separation of lactic acid from its major impurity (i.e., acetic acid) in fermentation broths (Lee et al., 2004) and recovery of fermentable sugars and ionic liquids that were used as pre-treatment solvents (e.g., to dissolve cellulose) (Mai et al., 2012). Table ...
Additionally, the recovery of the immune system may lead to the elimination of CAR-NK cells following infusion, as evidenced by the diminishing peaks observed after each dose. These findings suggest that the current design may not be optimal for CAR-NK cell therapy. Compared with the reported ...
Linear birefringence (LB) measurements versus temperature have been performed on K1-xRbxAlF4 (x = 0.04; 0.06; 0.09). The corresponding curves exhibit a universal behaviour: the ab-LB step at the II-IIIa transition (characteristic of a first order transition) as well as the LB's variations ...
Comparison of Pulse Based Clock Recovery Methods Comparing the pulse response clock locations for the bang-bang and the baud-rate type-A phase detectors, we observe that the baud-rate type-A clock location is to the right of the bang-bang clock location. This is typically due to the way ...
A double-blind, placebo-controlled, randomized phase III trial of gemcitabine plus bevacizumab versus gemcitabine plus placebo in patients with advanced pancreatic cancer: a preliminary analysis of Cancer and Leukemia Group B (CALGB) 80303. Background: In a phase II trial in 52 PC pts, GB ...
similar (47 in our study versus 50 in the Quant study). Also, in both studies there was no exclusion of participants based on number of episodes of progressive disease. The key difference in the study participants, however, is that our study only enrolled recurrent glioblastoma whereas the ...
The overall response rate was 20%, including two complete remissions without hematological recovery and one partial response. We also observed myeloid differentiation upon TCP/ATRA treatment in patients who did not reach clinical remission. Median overall survival (OS) was 3.3 months, and one-year ...